Pacira Pharmaceuticals (NASDAQ: PCRX) — Company Overview, News & Financial Data
Pacira Pharmaceuticals focuses on non-opioid pain management solutions, highlighted by its innovative product EXPAREL.
Pacira Pharmaceuticals
Pacira Pharmaceuticals (NASDAQ:PCRX) specializes in non-opioid pain management and regenerative health solutions to improve patients' journeys in acute care and ambulatory settings. Traded on the NASDAQ stock exchange under the ticker code PCRX, the company focuses on pioneering projects aimed at minimizing reliance on opioids for post-surgical pain management. Pacira's flagship product, EXPAREL, exemplifies their commitment to providing innovative, effective pain relief options. With a keen eye on expanding its portfolio, Pacira actively pursues research and development projects alongside strategic acquisitions to broaden its impact on pain management. The overarching objective is to offer safer, more effective alternatives that can significantly alter patient care standards and better respond to the urgent need for opioid alternatives in medical practice.
Snapshot
Operations
Products and/or services of Pacira Pharmaceuticals
- EXPAREL, a local anesthetic for postsurgical pain management.
- iovera°, a handheld device providing immediate and long-lasting pain relief through a novel cryoanalgesia technique.
- ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain.
- DepoFoam technology, a delivery system for sustained release of therapeutic agents.
- Nocita, a long-acting local anesthetic for post-surgical pain relief in pets.
- Pacira BioSciences Pipeline, focusing on developing innovative non-opioid pain management and regenerative health solutions.
Pacira Pharmaceuticals executive team
- Frank D. LeeCEO & Director
- Shawn M. CrossChief Financial Officer
- Kristen WilliamsChief Administrative Officer & Secretary
- Jonathan SloninChief Medical Officer
- Brendan P. TeehanChief Commercial Officer
- Lauren Bullaro RikerPrincipal Accounting Officer & Senior VP of Finance
- Susan MescoHead of Investor Relations
- Anthony Molloy IIIChief Legal & Compliance Officer
- Christopher C. YoungChief Manufacturing Officer
- Krys CorbettChief Business Officer
Latest news about Pacira Pharmaceuticals
Recent announcements
What Pacira Pharmaceuticals (PCRX) has told the market, newest first.
- NEWS_HALT halt | PCRXPrice sensitive
Key financials
Reported results for Pacira Pharmaceuticals, in USD.
- Market cap
- 1.5B
- Revenue (TTM)
- 746.2M
- P/E ratio
- 104.0
- EPS (diluted, TTM)
- 0.3
- Dividend yield
- —
- Profit margin
- 2.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 726.4M | 33.3M | 7M | |
| 701M | -73.4M | -99.6M | |
| 675M | 87.7M | 42M | |
| 666.8M | 60M | 15.9M |